What does a cannabis evidence comparison chart show? It shows exactly who was studied, the cannabis product or formulation involved, the outcome measured, and how certain the finding is. That matters because a result for one group, product, and outcome does not automatically answer a different question about CBD, THC, gummies, sleep, pain, or another population.
This chart is a tool for reading research, not a diagnosis, dosing guide, clearance tool, or purchase recommendation. Use the row that matches your question, then follow its source link or the appropriate official reference.
How to read each row
Start with four fields: population means the people in the study; formulation means the exact product form or medicine studied; outcome means what researchers measured; and uncertainty tells you why a result may not carry over to another person or product.
| Question | Population | Compound or formulation | Measured outcome | What the source says | Uncertainty shown |
|---|---|---|---|---|---|
| Chronic pain | People in 47 studies of chronic pain other than cancer pain | Cannabis or cannabinoids; the source groups several products together | At least a 30% reduction in pain | NCCIH reports 29% of people taking cannabis/cannabinoids and 26% taking placebo reached that outcome in a 2018 review. | The difference may be too small to matter to patients, and adverse events were more common with cannabis/cannabinoids. |
| Neuropathic pain | Adults in 16 studies | Mostly nabiximols, a mouth spray containing THC and CBD | Pain relief versus placebo | NCCIH describes low- to moderate-quality evidence of better pain relief than placebo. | Small study numbers and possible bias made the data unreliable; results were inconsistent. |
| Rare seizure disorders | People with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex | Purified CBD prescription medicine | Seizures associated with those named conditions | FDA says it has approved one CBD product for these specific seizure indications. | This is an approved prescription product and named population, not a finding about retail CBD products or other outcomes. |
| Cancer-chemotherapy nausea and vomiting | 214 people receiving chemotherapy | Oral delta-9-THC compared with prochlorperazine | Reduction of nausea and vomiting | A 1982 PubMed-indexed clinical trial reported the two study drugs were equally efficacious across the regimens and tumor types included. | The trial also reported more drug-related effects with THC, including less ability to concentrate, less social interaction, and less activity. |
Which population, outcome, and formulation does each finding describe?
Read across, not down. The chronic-pain row describes a mixed group of cannabis or cannabinoid interventions and one pain-reduction threshold; it is not a CBD-gummy row. The neuropathic-pain row is mainly about a THC-and-CBD mouth spray, not every THC/CBD blend. The seizure row is about a purified prescription CBD medicine in three named rare seizure disorders. The chemotherapy row is about oral delta-9-THC and prochlorperazine in people receiving chemotherapy.
That distinction is especially useful when comparing claims around individual compounds. Our CBD evidence overview explains the difference between CBD research and broad cannabis claims, while the THCV research profile covers a different, early-stage cannabinoid record.
How does the chart show uncertainty and missing evidence?
Use plain labels rather than turning a study result into a yes-or-no answer:
| Chart label | What it means for you |
|---|---|
| Direct finding | The row states the population, formulation, comparator, and measured outcome from a named source. |
| Limited or low-quality | The source identifies issues such as small studies, possible bias, inconsistent results, or a result that may be too small to matter. |
| Not transferable | A result belongs to a specific medicine, product form, or population and should not be used as a stand-in for another one. |
| Not assessed in this chart | This chart has no sourced row for that exact population, formulation, and outcome. It cannot tell you the answer for that combination. |
For example, the pain rows cannot tell you whether a retail gummy produces the same outcome as the products studied. The FDA says that cannabis or cannabis-derived products not reviewed through its drug-approval process have not been evaluated for effectiveness, proper dosage, drug interactions, or safety concerns in that process. FDA cannabis regulation information explains that distinction.
Plain-language glossary
- Comparator: what the study product was measured against, often a placebo or another medicine.
- Formulation: the specific form studied, such as a purified prescription product, a mouth spray, or oral delta-9-THC.
- Outcome: the result researchers counted or measured, such as a defined pain-reduction threshold or nausea and vomiting.
- Placebo: an inactive comparison used in some studies.
- Adverse event: an unwanted effect reported during a study.
- Applicability: whether a study’s people, product, and outcome match the question you have.
Do not confuse BSA in the chemotherapy trial with a legal evidence term: in that study, BSA was used for body-surface-area categories in the trial’s THC protocol. It does not make the paper an “Evidence Act and BSA” comparison chart.
What legal context belongs beside an evidence row?
As of the October 5, 2026 capture date, the FDA says the Agriculture Improvement Act of 2018, Pub. L. 115-334 (the 2018 Farm Bill), defined hemp as Cannabis sativa L. and its listed derivatives with no more than 0.3% delta-9 THC on a dry-weight basis, while preserving FDA authority over products containing cannabis-derived compounds. That legal definition is not evidence that a particular formulation has a particular health outcome.
For a separate safety reference, the CDC’s cannabis health-effects page says health risks are associated with cannabis regardless of how it is used and notes that edibles have different risks, including a greater risk of poisoning. Keep legal status, product identity, and research findings in separate columns; combining them can make a chart say more than its sources do.
Use the chart for the question you actually have
If your question is about sleep, start with the population and product form in sleep research rather than borrowing a pain result. If you are comparing a marketing claim with an ingredient study, use the study’s outcome and uncertainty fields before treating the claim as an outcome.
Before you rely on a cannabis comparison
- Match the population, formulation, comparator, and outcome to your own question.
- Open the linked official or published source when a row matters to your decision.
- Keep a blank or “not assessed” field blank; it means this chart cannot answer that exact question.
- For a question about a medical condition or medicines you use, take the source and your question to a clinician.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.